Epitalon: Benefits, Dosage & FDA Status
Epitalon (Epithalon, AEDG)
A synthetic tetrapeptide that reportedly upregulates telomerase activity. Russian longevity studies suggest mortality reductions but Western RCTs are absent.
FDA Status
Not FDA-approved — Russian-origin research peptide
Typical Dose
5–10 mg daily for 10–20 days, cycled (subcutaneous)
Evidence Grade
C+Preclinical evidence + anecdotal clinical use
Half-Life
Minutes (effects attributed to gene-expression downstream)
Routes of Administration
subcutaneous, intranasal
First Synthesized
1980s
Clinics Indexed
47 providers have offered Epitalon in our tracked directory.
Mechanism of Action
AEDG tetrapeptide that has been reported to upregulate telomerase activity and modulate pineal-pituitary signaling in animal and human studies.
Key Reported Benefits
- ✓Telomerase upregulation (preclinical)
- ✓Sleep/circadian normalization
- ✓Anti-aging signals
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade C+ indicates preclinical evidence + anecdotal clinical use.
Reported Side Effects
- •Generally well-tolerated
- •Sedation in some users
Contraindications
- ⚠Pregnancy
- ⚠Active malignancy
Regulatory & Safety Context
FDA status: Not FDA-approved — Russian-origin research peptide
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
See state-by-state legality: US peptide legality by state →
References
Selected primary literature on Epitalon. Full PubMed records linked. Additional citations are available on request.
Last reviewed: 2026-04-30
Related Peptides
GHK-Cu
B+A naturally occurring copper-binding tripeptide that modulates 4,000+ human genes. The most studied peptide for skin rejuvenation with both preclinical and clinical topical evidence.
CJC-1295 (no DAC)
BA growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
Ipamorelin
BA selective growth hormone secretagogue that triggers GH release from the pituitary without significantly raising cortisol or prolactin. The safest GH peptide with the fewest side effects.
Sermorelin
B+The original synthetic GHRH(1–29) and the most accessible GH-stimulating peptide for age-related hormone decline. Stimulates the body's own pulsatile GH release rather than replacing it.
MK-677
B+An orally active ghrelin-receptor agonist that drives 24-hour increases in GH and IGF-1. Technically a non-peptide small molecule but always grouped with GH peptides.
GHRP-2
BA potent synthetic ghrelin-mimetic GH secretagogue. Drives strong GH spikes but raises cortisol and prolactin more than newer alternatives like Ipamorelin.